Tempus AI reported a significant increase in revenue, achieving $1.27 billion in 2025, which represented an 83.4% increase from $693.4 million in 2024. The company also reported Q4 2025 revenue of $367.21 million, up from $200.68 million a year earlier, reflecting strong growth in diagnostics and data businesses. In Q1 2026, Tempus AI's revenue increased by 36.1% year-over-year to $348.1 million, compared to $255.7 million in Q1 2025. Additionally, the company completed an IPO on Nasdaq in March 2025, raising $410 million to expand its AI-driven precision medicine data platform and international biomarker analytics capabilities. Furthermore, Tempus AI's adjusted EBITDA turned positive in Q4 2025, marking a key milestone toward eventual profitability after prior losses.